Introduction
Carcinogenesis is a multistep process involving the activation of proto-oncogenes and the loss of tumor suppressor genes (Fearon and Vogelstein, 1990) . During lymphomagenesis, activation of the protooncogene bcl-2 by the t(14;18) chromosomal translocation represents one of these steps (Bakhshi et al., 1985; Cleary and Sklar, 1985) . The encoded 26 kDa Bcl-2 protein is a potent inhibitor of apoptotic cell death in many systems (reviewed in Hale et al., 1996) , and this property is thought to account for its oncogenic potential in lymphoma (McDonnell and Korsmeyer, 1991) . Therefore, the inhibition of apoptosis could be a general step during multistep carcinogenesis.
Bcl-2 is an integral membrane protein localised to mitochondria, the endoplasmic reticulum and the nuclear envelope (Monaghan et al., 1992) . The biochemistry of its functioning is still unknown. Bcl-2 can interact with related proteins, among them other death inhibitors such as Bcl-x L (which can be counteracted by a smaller splice variant, Bcl-x S ) and deathpromoting homologues like Bax or Bak (reviewed in Farrow and Brown, 1996) . Homo-and heterodimerization between the members of this so called bcl-2 family is believed to represent the physical basis of their apoptosis-regulating potential.
Bcl-2 expression has not only been detected in lymphoid tumors but also in several carcinomas including those of the intestinal tract (Hague et al., 1994) , the lung (Jiang et al., 1995) , and of hormoneregulated tissues such as the ovaries (Eliopoulos et al., 1995) , the prostate and the breast. In prostate carcinoma, Bcl-2 expression could be related to metastatic hormone-insensitive tumor stages and thus seems to play a role in late tumor progression (McDonnell et al., 1992) . In contrast, in mammary carcinoma Bcl-2 expression correlates with markers of good prognosis like estrogen receptor and is often lost in progressed disease (Gee et al., 1994; Leek et al., 1994) suggesting that expression (i) is estrogendependent and (ii) might play a role in early tumor development. On the other hand, loss of Bax expression correlates with bad prognosis in mammary carcinoma (Bargou et al., 1995; Krajewski et al., 1995) . Bcl-2 was upregulated by estradiol in MCF-7 cells, suppressing tamoxifen-induced apoptosis (Wang and Phang, 1995) .
In this paper we have addressed the question of whether and how Bcl-2 contributes to mammary tumorigenesis. To these ends we have generated WAP-bcl-2 transgenic mice which overexpress Bcl-2 in their lactating mammary glands. These mice allowed us to study (i) the eect of Bcl-2 expression on postlactational mammary gland involution, a remodelling process of the milk-secreting epithelium characterized by extensive apoptotic death of alveolar cells, and (ii) the in¯uence of Bcl-2 expression on spontaneous and cMyc-induced tumorigenesis of the mammary gland. Our results suggest that Bcl-2 contributes to mammary tumorigenesis by inhibiting apoptosis.
Results
Generation of transgenic mice overexpressing a WAPbcl-2 transgene in their lactating mammary glands In order to direct high level transgene expression to alveolar cells of lactating mammary glands we have used the promoter of the mouse whey acidic protein (WAP) gene (Burdon et al., 1991) . As depicted in Figure 1a , the WAP-bcl-2 transgene consists of the 2.9 kb BglII-mouse WAP gene fragment, comprising 1.6 kb of the WAP promoter and the ®rst three exons separated by their respective introns, fused to the SV40 polyadenylation sequence. The human bcl-2a cDNA has been cloned into the unique KpnI site upstream of the translation initiation codon in the ®rst exon of the WAP gene. Microinjection of this construct into the pronuclei of single cell B6D2F1 mouse embryos and their transfer into the oviducts of pseudopregant foster mothers resulted in ®ve transgenic founder mice, all transmitting the transgene to their progeny as determined by Southern blotting of genomic DNA (Figure 1b) . Expression analysis, carried out by Northern blotting of total RNA derived from lactating mammary glands, revealed two transgeneexpressing mouse lines, line 965 and line 1182 ( Figure  1c ). As expected from the lack of endogenous polyadenylation signals on the bcl-2 cDNA clone, the transcripts were larger than 1 kb in size; the observed size of approximately 3 kb suggests the occurrence of incomplete splicing of the WAP introns. In addition, there were no cross-hybridizing endogenous bcl-2 transcripts detectable in the lactating mammary glands. The transgene-derived transcripts were translated into protein of the correct size indicating that translation terminated at the endogenous stop codon of the bcl-2 cDNA (see Figure 2 and data not shown). Immunohistochemical examination revealed strong Bcl-2 expression in alveolar cells which was uniform over the whole mammary gland (not shown).
Inhibition of alveolar cell apoptosis during involution by Bcl-2
During the postlactational mammary gland involution, the alveolar structures formed by epithelial milkproducing cells characteristic of the lactating mammary gland are remodeled to a system of branching ducts which is similar to the virgin gland (Walker et al., 1989) . Since the alveolar cells disappear by apoptosis hereby (Strange et al., 1992) , we have compared the involution process seen in WAP-bcl-2 transgenic mice (line 1182) with wildtype controls.
First, transgene expression was examined in mammary glands at dierent times of involution by Western blotting using a monoclonal antibody speci®c for the human Bcl-2 protein. A 26 kDa protein, indicative of the transgene-derived human Bcl-2 protein, could be detected only in protein extracts derived from transgenic mice (Figure 2 ). During the ®rst 3 days of involution, Bcl-2 protein was present in the mammary glands of transgenic mice, decreasing at day 4, thus enabling us to study the eects of the Bcl-2 overexpression on alveolar cell apoptosis during involution.
To that end we speci®cally stained apoptotic cells in tissue sections using the TUNEL method (Gavrieli et al., 1992) . Figure 3 shows typical examples of the assay on paran-embedded tissue of wildtype vs transgenic mice after dierent durations of weaning. A quantitation of the apoptotic cells per ®eld is given in Figure 4 and Table 1 . The numbers of stained cells in the lymph nodes on the same sections were used as an internal control and were not signi®cantly dierent between transgenic and wildtype mice (not shown).
In wildtype mice, 2 days after lactation signi®cant numbers of apoptotic cells lining the alveolar lumina could be detected, some shed into the lumen; apoptotic cells reached a peak in number at day 3 of involution ( Figure 3a and c) . At day 4, when most of the alveoli had collapsed, still high numbers of apoptotic cells were present (Figure 3e ). In contrast, mammary glands of transgenic mice displayed a signi®cantly reduced rate of apoptosis at days 2 and 3 (Figure 3b and d) . Western blot analysis of transgenic Bcl-2 expression in involuting mammary glands. Protein extracts from mammary glands of transgenic WAP-bcl-2 mice (+) or non-transgenic littermates (7) at days 1, 2, 3 and 4 of involution were analysed for transgene expression using the monoclonal antibody 124 which is speci®c for the human Bcl-2 protein (arrow)
Stained nuclei were barely detectable at day 2, and even at day 3 their number did not exceed that of wildtype mice at the previous day of involution (Figure 4) . Interestingly, however, at the fourth day of involution the number of apoptotic cells was higher than at day 3 exceeding even the day 4 value of wildtype mammary glands, concommitant with the sharp decline in transgene expression at that timepoint. Histologically, wildtype and transgenic glands were indistinguishable. Similar results were obtained with the second transgene-expressing mouse line, 965, at day 3 after weaning (not shown). Taken together these data clearly demonstrate an inhibition of the involutionassociated apoptosis of alveolar cells by the WAP-bcl-2 transgene.
Since no histological dierences between involuting mammary glands of wildtype and transgenic mice could be detected, we wondered whether the transgene elicits any eects on gene expression. The comparison of the expression levels of the involution-associated genes SGP-2, p53 and TGF-b1 (Strange et al., 1992) between transgenic and wildtype mice revealed no signi®cant dierences during involution ( Figure 5 ). In both wildtype and transgenic mammary glands, SGP-2 expression was sharply induced at day 2 of involution, in transgenics to a somewhat larger extent, then again declining in expression thereafter. Similarly, both p53 and TGF-b1 mRNA were induced equally in glands of wildtype and transgenic animals during involution, peaking at day 4. Furthermore, the involution- 
) and 4 (e, f) of involution. TUNEL assays on paran sections of the inguinal mammary glands were performed as described in Materials and methods. Apoptotic nuclei are labeled in red. Bar represents 100 mm. In the upper half of (f) a part of the lymphnode is visible WAP-bcl-2 transgenic mice R Ja Èger et al associated TIMP1 and junD induction (Feng et al., 1995) was not in¯uenced by the expression of the transgene (not shown). As a further control, the hormone-dependent expression of the b-casein gene was monitored. Similar to wildtype mice, in mammary glands of transgenics the b-casein expression level decreased during involution. However, there seemed to be increased expression at lactation in the transgenic mammary gland as compared to the wildtype. The same was observed for the endogenous WAP transcript (not shown). Thus, Bcl-2 seems to exert its antiapoptotic function neither via repression of the involution-associated transcripts analysed nor by the preservation of dierentiation as determined by histological appearance and by milk-gene expression levels.
Acceleration of myc-induced mammary tumorigenesis by Bcl-2
In the WAP-bcl-2 transgenic mice, even after multiple pregnancies, no tumors were observed during the more than 1.5 year period of investigation. In order to ascertain whether transgenic Bcl-2 expression had any cooperative eect on tumorigenesis we crossed the WAP-bcl-2 transgenics with MMTVmyc transgenic mice. These mice develop mammary tumors spontaneously after a certain latency period due to transgenederived c-Myc expression in their mammary glands (Stewart et al., 1984) . Double transgenic WAP-bcl-2/ MMTVmyc mice were compared to their single transgenic littermates. To exclude an in¯uence of the genetic background only F1 female ospring from such crosses were included in the analysis. These mice were kept in forced breeding to ensure continuous high levels of transgene expression and monitored weekly for the presence of tumors. As shown in Figure 6 , in double transgenic mice the latency period required for tumor development was signi®cantly shortened in comparison to single transgenic MMTVmyc controls: Whereas in the latter the latency period was 18.3+3.3 weeks, double transgenic mice required only 13.6+0.9 weeks (line 1182) or 14.6+2 weeks (line 965) for the development of detectable tumors. Because both transgenes are driven by dierent promoters we were interested in whether transgenic Figure 5 Gene expression during lactation (day 0) and involution (days 1, 2, 3 and 4) in WAP-bcl-2 transgenic mice (+) and non-transgenic littermates (7). 15 mg total RNA of mammary glands were analysed by hybridization with 32 P-labeled cDNA probes speci®c for the indicated genes (see Materials and methods for details). To compare the amounts of RNA loaded in between the same timepoints, the blot was also hybridized with a probe representing GAPDH cDNA. Note that GAPDH is slightly induced during involution Bcl-2 was actually expressed in the tumors of double transgenics, i.e. a cell type expressing both transgenes gave rise to the tumors. Figure 7 shows results from a typical Western blot con®rming transgenic Bcl-2 expression in the c-Myc-induced tumors. The expression of c-Myc, besides inducing cells to proliferate, can also induce apoptosis in vitro, and this apoptosis can be blocked by Bcl-2 (Fanidi et al., 1992) . Therefore, our ®ndings of accelerated tumor development in double transgenic WAP-bcl-2/MMTVmyc mice prompted us to investigate the rate of apoptosis in their mammary gland epithelium. As shown in Figure 8 , MMTVmyc single transgenic mice displayed a very high degree of apoptosis in their mammary glands at gestation, exceeding even the rate at day 3 of involution of wildtype mice (Figure 4) . The inability to lactate which we observed in these animals may in part be explained by this ®nding. Although the ability to lactate was not restored by the WAP-bcl-2 transgene, mammary glands of double transgenic WAP-bcl-2/ MMTVmyc mice displayed signi®cantly reduced numbers of apoptotic cells (see Figure 8 and Table 1 ).
Discussion
The Bcl-2 protein is capable of preventing apoptotic cell death induced by a variety of stimuli in dierent cell types (reviewed in Hale et al., 1996) . Based on experimental overexpression in transgenic mice, this has so far been demonstrated for lymphoid cells (McDonnell et al., 1989) , for neurons of the central nervous system (Martinou et al., 1994) , for hepatocytes (Lacronique et al., 1996) and, recently, for retinal photoreceptors (Chen et al., 1996) . In this paper we describe transgenic mice which overexpress Bcl-2 under the control of the murine WAP promoter in their lactating mammmary glands. This expression extended to the early phase of postlactational involution of the mammary epithelium and led to the inhibition of the apoptosis of alveolar cells normally seen in wildtype mammary glands. In addition, in a recent publication the WAP-bcl-2 transgene has been shown to inhibit the apoptosis of the body cells in the terminal endbuds of the developing mammary glands (Humphreys et al., 1996) . Furthermore, we demonstrate that expression of c-Myc, when targeted to the mammary glands of transgenic mice by means of the MMTV LTR, besides leading to mammary tumors, induces fulminant apoptosis of mammary epithelial cells, which could be partially inhibited by the WAP-bcl-2 transgene. As coexpression of Bcl-2 shortened the latency period required for tumor development in MMTVmyctransgenic mice, we conclude that the c-myc and bcl-2 proto-oncogenes can cooperate in mammary tumorigenesis by dierentially modulating apoptosis.
Inhibition of mammary gland involution
Bcl-2 is the ®rst described member of a family of related proteins which in¯uence apoptosis (reviewed in Farrow and Brown, 1996) . In addition to antiapoptotic members like Bcl-2 or Bcl-x L there exist pro-apoptotic homologous proteins like Bax, Bak or Bcl-x S . It is thought that their relative amounts determine whether a cell will die or survive and that homo-and heterodimerization between the family WAP-bcl-2 transgenic mice R Ja Èger et al members represents the physical basis of their apoptosis-modulatory potential (Zha et al., 1996) . Upregulation of bcl-x S and Bax has been observed during mammary gland involution (Heermeier et al., 1996) . During the ®rst 2 days of involution a sixfold increase in the ratio of bcl-x S to bcl-x L RNA was found; the number of Bax expressing cells peaked at day 3 of involution, coincident with a peak in the number of apoptotic cells, and some of the Bax expressing cells showed characteristic apoptotic morphology (Heermeier et al., 1996) . It is not known, however, whether this upregulation is of functional signi®cance for the induction of apoptosis in alveolar cells. Given the well-established capability of Bcl-2 to heterodimerize with and counteract Bcl-x S or Bax (Oltvai et al., 1993; Sato et al., 1994) , the inhibition of apoptosis of alveolar cells in the mammary glands of WAP-bcl-2-transgenic mice is consistent with the causal involvement of these pro-apoptotic family members in the control of alveolar cell death.
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In an attempt to unravel how Bcl-2 might exert its anti-apoptotic function we analysed whether the expression of genes presumed to play a role in mammary gland involution (Strange et al., 1992) was in¯uenced by the transgene. SGP-2, for example, is not only induced during mammary gland involution but also during regression of the prostate upon androgenablation and in dierent tumor cell lines induced to undergo apoptosis (Wong et al., 1993 (Wong et al., , 1994 . Overexpression of TGF-b1 and p53, which are both induced during involution, led to apoptosis of mammary alveolar cells in transgenic mice (Kordon et al., 1995; Li et al., 1996a) , pointing towards a functional role of these molecules in involution-associated apoptosis as well. In the mammary glands of WAP-bcl-2 transgenic mice the expression of these genes was not dramatically altered as compared to wildtype mice, indicating that Bcl-2 does not act via modulation of their expression. If they play any role in apoptosis of alveolar cells, then Bcl-2 must act downstream. Notably, mammary gland involution is unaltered in p53 7/7 mice suggesting that alveolar cells die in a p53-independent manner (Li et al., 1996b) .
The pattern of gene expression re¯ects the differentiation of the mammary epithelium. This is evident from the loss of milk protein gene expression during involution. As were the involution-associated transcripts, the expression of the milk protein genes bcasein and WAP was unaltered in WAP-bcl-2 transgenic mice. In addition, and perhaps surprisingly, alveolar collapse was not delayed in these mice. This is consistent with the discrimination of two independent phases of involution, one characterized by apoptosis of alveolar cells, and a later where the activation of extracellular matrix (ECM)-degrading matrix metalloproteinases leads to alveolar collapse and remodelling of the mammary gland (Lund et al., 1996) . Therefore, it is unlikely that the disruption of the ECM triggers the apoptosis of alveolar cells as has been concluded from in vitro experiments where ECM provided a survival signal to mammary epithelial cells (Boudreau et al., 1995 (Boudreau et al., , 1996 Pullan et al., 1996) . However, in the WAP-bcl-2 transgenic mice the increased apoptosis observed at day four of involution could well be explained by this, as transgene expression dropped at this timepoint and alveolar structures were disrupted, most likely due to degradation of the ECM. This could induce persisting alveolar cells to undergo apoptosis. Of note, preliminary observations revealed that there is no accumulation of epithelial cells in the mammary glands of older females after four lactation periods. In separating dedierentiation from apoptosis, the WAP-bcl-2 transgenic mice are so far unique compared with other transgenic mice where the mammary gland-speci®c overexpression of hGH, TGFa or desIGF-1 led to a delayed involution which was accompanied by the preserved histological differentiation of the milk-producing epithelium or expression of milk protein genes Bchini et al., 1991; Sandgren et al., 1995; Hadsell et al., 1996) .
Cooperation between c-Myc and Bcl-2 during mammary carcinogenesis
Tumorigenesis is a multistep process involving the activation of proto-oncogenes, the inactivation of tumor suppressor genes and, possibly, further epigenetic changes (Fearon and Vogelstein, 1990) . This is most evident from studies with oncogene bearing transgenic mice, where only solitary, monoclonal tumors arise after a latency period indicating the requirement for further genetic alterations (reviewed in Adams and Cory, 1991). In our experiments, for example, MMTVmyc transgenic mice (where c-Myc overexpression is targeted to the mammary glands) required a latency period of 18 weeks (mean) for the development of visible and palpabel mammary tumors. In addition, the mammary epithelium may possess intrinsic properties which may reduce the risk of tumor development. Firstly, the epithelium is under hormonal control, and possibly only a certain hormonal constellation will favor transformation by c-Myc. Secondly, in the virgin mouse the mammary epithelium undergoes cycles of proliferation and regression even in the absence of pregnancy (Andres et al., 1995) . The concommitant elimination of epithelial cells by apoptosis may also aect tumorigenically altered cells and thus serve as a natural cancer protection.
Since Bcl-2 did not in¯uence gene expression or dierentiation of the mammary epithelium in WAP-bcl-2 transgenic mice a possible in¯uence on tumour proneness, as perhaps elicited by lactogenic hormones, is unlikely. Of interest, both single transgenic MMTVmyc and double transgenic WAP-bcl-2/ MMTVmyc transgenic female mice were incapable of properly nursing their progeny. Thus, although not tested, immediate onset of involution after delivery of the litters can be expected, and Bcl-2 should delay the associated apoptosis in the double transgenics. Furthermore, c-Myc has been shown to induce apoptosis when overexpressed in ®broblasts under restrictive growth conditions . Consistent with this observation, we observed fulminant apoptosis of mammary epithelial cells in MMTVmyc transgenic mice. This may represent an inherent tumor suppressive property of the c-myc gene. As in WAP-bcl-2/ MMTVmyc double transgenic mice this apoptosis was reduced while tumor development was accelerated, we conclude that Bcl-2 contributes to c-Myc-induced mammary tumorigenesis by preventing apoptosis.
These ®ndings are highly reminescent of the cooperation between c-Myc and Bcl-2 in the lympho-magenesis observed in mice harboring an Em-mycconstruct and an Ig-bcl-2 minigene as transgenes (Marin et al., 1995) . In these animals, Bcl-2 has been shown to suppress c-Myc-induced apoptosis. Furthermore, Bcl-2 prolonged the lifespan of pre-B cells leading to the expansion of a polyclonal B cell pool in the spleens of Ig-bcl-2 transgenic mice (McDonnell et al., 1989) . In the WAP-bcl-2 transgenic mice this may correspond to the delayed involution-associated apoptosis of alveolar cells. However, while the expanded B-cell pool eventually gave rise to lymphoma (McDonnel and Korsmeyer, 1991) , in WAP-bcl-2 transgenic mice no mammary tumors have been observed even after more than 1.5 years. The principal dierence here is that in mammary glands of WAP-bcl-2 transgenic mice no cell accumulation takes place, most likely due to enhanced apoptosis at day 4 of involution.
Can the ®nding of cooperativity between c-Myc and Bcl-2 in both mammary carcinoma and lymphoma be extrapolated to a model of multistep carcinogenesis where the disruption of the apoptotic machinery would be a necessary step? This would require that certain oncogenic alterations of a cell would per se lead to apoptosis rather than transformation. Indeed, this has been evidenced by the transforming gene, E1A, of adenovirus which requires the apoptosis-inhibitory action of the adenoviral E1B gene in order to transform cells (Debbas and White, 1993) . In vivoexperimental support for this concept has been published scarcely. In one study, disruption of pRb function in retinal cells of transgenic mice was leading to tumor formation only in the absence of wildtype p53 function, which otherwise induced apoptosis of the retinal cells (Howes et al., 1994) . In a recent study, the expression of Bcl-x L in pancreatic b-cells of transgenic mice accelerated tumor development induced by SV40 large T antigen (Naik et al., 1996) . The widespread expression of Bcl-2 in epithelial human tumors (see Introduction) as well as the loss of wildtype p53 function in the majority of advanced human carcinomas point towards the same conclusion.
Taken together, our results show that c-Myc and Bcl-2 cooperate in mammary carcinogenesis in transgenic mice by dierentially modulating apoptosis. As expression of both oncogenes has been detected in human breast cancer, this ®nding may be of relevance for the human situation.
Materials and methods

Cloning
The bcl-2a cDNA was excised from the Bcl-2/PURO vector (Fanidi et al., 1992) by EcoRI digestion and after addition of EcoRI ± KpnI linkers cloned into Asp 718-restricted pBS WAP (Burdon et al., 1991) to generate WAP-bcl-2. The 3.5 kb BglII Fragment of WAP-bcl-2 was inserted into BamHIdigested pSV-T7 (GuÈ nthert et al., 1991) from which part of the polylinker had been removed before by EcoRI digestion and religation. Orientation was checked by multiple restriction digests. The SSpI fragment of the resulting plasmid, pSVWAPbcl-2, containing the WAP promoter, the bcl-2a cDNA, part of the WAP gene and the SV40 polyadenylation signal of pSV-T7 was used for microinjection.
Generation of transgenic mice
SSpI-fragments of the pSVWAPbcl-2 DNA were microinjected into pronuclei of zygotes generated from F1 hybrid female mice (C57bl/66DBA/2) mated to DBA/2 males. One or two cell embryos surviving micromanipulation were transferred into the oviducts of pseudopregnant foster mice according to published procedures (Hogan et al., 1986) . From resulting ospring DNA was extracted from tail biopsies by incubation in 750 ml of tail buer (50 mM Tris, pH 8.0, 100 mM EDTA, 100 mM NaC1, 1% (w/v) SDS, 0.5 mg/ml proteinase K) at 558C for 14 h. Following addition of 300 ml 5 M NaC1 solution precipitated proteins were sedimented in a microfuge and the DNA was puri®ed by Isopropanol precipitation followed by two washes in 500 ml 80% ethanol. 20 mg of tail DNA was BamHI-digested and after gel electrophoresis blotted onto Hybond N + membrane (Amersham). Blots were probed with 32 Plabeled bcl-2a cDNA and after washing in 26SSC, 0.1% (w/v) SDS and 16SSC/0.1% (w/v) SDS at 658C (two times 10 min each) exposed to Kodak X-ray ®lm.
Induction of involution
WAP-bcl-2 transgenic mice or non-transgenic littermates were allowed to establish lactation after the ®rst pregnancy. The littersize was adjusted to ®ve pups. The young were removed after 10 days of lactation and involuting abdominal mammary glands were prepared at various times after forced weaning.
Tumorigenesis
Male MMTVmyc transgenic mice purchased from Charles River (Sulzfeld, Germany) were bred to WAP-bcl-2 female mice. The MMTVmyc transgene in the F1 descendents was identi®ed by PCR using the primers myc1 (5'-CCC AAG GCT TAA GTA AGT TTT TGG-3') and myc2 (5'-GGG CAT AAG CAC AGA TAA AAC ACT-3'). To that end, 5 ml of tail DNA was subjected to 31 cycles (1 min 958C, 1 min 588C, 1 min 728C) in 50 mM (w/v) KC1, 2 mM (w/v) MgC1 2 , 10 mM (w/v) Tris (pH 8.3), 200 mM (w/v) each of dGTP, dATP, dTTP, dCTP and 150 nM primers in a total volume of 50 ml. Double transgenic WAP-bcl-2/MMTVmyc or single transgenic MMTVmyc females, 6 weeks of age, were continously bred to male B6D2F1 mice and monitored weekly for the presence of tumors by visual examination and palpation.
RNA preparation and analysis
Tissue RNA was prepared using the guanidiniumisothiocyanate-method (Chirgwin et al., 1979) . 15 mg of total RNA was loaded onto an 1% agarose gel supplemented with 3.3% (w/v) formaldehyde and run in MOPS buer (20 mM morpholino-propyl-sulphonate, 5 mM sodium acetate, 0.5 mM EDTA, pH 7.0). The RNA was transferred to a nylon membrane (Hybond N + , Amersham) and hybridized to 32 P-labeled DNA probes. Filters were washed twice in 26SSC, 0.1% (w/v) SDS and twice in 16SSC, 0.1% (w/v) SDS at 658C, 10 min each wash.
The probes used were: bcl-2 cDNA (released from Bcl-2/ PURO); b-casein and TGF-b1 probes were kindly provided by A Cato and the SGP-2 probe by A-C Andres; the mouse p53 probe was a gift of B Baumann.
Protein preparation and analysis
Tissues were snap frozen and pulverized in liquid nitrogen and suspended in protein buer (50 mM Tris-HC1 pH 6.8; 2.5% (w/v) SDS). After heating to 1008C for 10 min the samples were soni®ed and centrifuged. Supernatants were taken and protein concentrations determined spectropho-tometrically. After adding 1/10 volume of sample buer (600 mM Tris pH 6.8, 8% (w/v) SDS, 20% (v/v) bmercapto-ethanol) and heating to 1008C for 10 min, 50 mg of proteins were electrophoresed on a 12.5% SDSpolyacrylamid gel (Laemmli, 1970) and transferred to a nitrocellulose membrane by electroblotting. After blocking in 5% (w/v) dry milk in PBS containing 0.3% (v/v) Tween 20 the ®lter was incubated with a mouse monoclonal antihuman bcl-2 antibody (clone 124, Genosys) followed by a horseradish peroxidase-conjugated anti-mouse antibody. Bound immunoglobulins were detected using the ECL system (Amersham).
Detection of apoptotic cells in tissue sections
Apoptotic nuclei were stained using the apoptag kit (Oncor) following the protocol of the manufacturer with slight modi®cations. Paran sections (8 mm) of formaline®xed mammary glands were deparanized, incubated with proteinase K (20 mg/ml) for 15 min at room temperature and then with 2% (v/v) H 2 O 2 in PBS for 30 min at room temperature. In order to label 3'-OH ends, terminal deoxynucleotidyl transferase (TdT) (Oncor) diluted in reaction buer was added. The reaction buer contained digoxigenin-labeled nucleotides. After a 1 h incubation at 378C the reaction was stopped with stop/wash buer at 378C (30 min), followed by washing in PBS. The sections were exposed to peroxidase-conjugated anti-digoxigenin immunoglobulin for 30 min at room temperature, washed again and treated with 3,3-amino-9-ethyl carbazole/H 2 O 2 for the colour reaction. The sections were embedded in glycergel (Dako) after counterstaining with hematoxylin. To count apoptotic nuclei 15 ®elds each on two sections of each sample were examined at a magni®cation of 6200.
